Table 8 Overexpression of TPX2 promotes the resistance of MHCC97-L cells to antitumor drugs, TKIs and chemotherapies.

From: TPX2 enhances the transcription factor activation of PXR and enhances the resistance of hepatocellular carcinoma cells to antitumor drugs

Antitumor drugs

Control

TPX2

IC50 values (μmol/L)

sorafenib

1.86 (1.30–1.98)

4.84 (2.70–5.94)

lenvatinib

1.94 (1.85–2.36)

5.73 (4.89–6.17)

regorafenib

1.50 (1.10–1.61)

4.93 (4.55–5.26)

cabozantinib

1.47 (1.01–1.93)

5.03 (4.99–5.31)

doxorubicin

0.25 (0.10–0.33)

0.82 (0.60–1.05)

paclitaxel

22 (13.1–36.5) (nmol/L)

0.15 (0.04–0.33)

etoposide

0.38 (0.20–0.51)

1.32 (0.99–1.80)

irinotecan

0.43 (0.25–0.68)

0.97 (0.80–1.11)

  1. IC50 values (μmol/L) were shown as median values (95% confidence interval)
Back to article page